|
US2811483A
(en)
*
|
1954-12-09 |
1957-10-29 |
Pfizer & Co C |
Pharmaceutical composition and process for preparing the same
|
|
DE1091289B
(de)
*
|
1956-01-25 |
1960-10-20 |
Hans Lowey |
Verfahren zur Herstellung einer oral anzuwendenden Arzneiform mit verlaengerter Wirkungsdauer
|
|
US2921001A
(en)
*
|
1957-04-16 |
1960-01-12 |
Sterling Drug Inc |
Multi-layered pill or tablet with indicating lamination
|
|
NL109170C
(en:Method)
*
|
1958-02-03 |
|
|
|
|
GB906422A
(en)
*
|
1958-05-02 |
1962-09-19 |
Wellcome Found |
Improvements in and relating to prolonged acting pharmaceutical preparations
|
|
US3131123A
(en)
*
|
1959-03-13 |
1964-04-28 |
Lab Francais De Therapeutique |
Enteric tablets and manufacture thereof
|
|
US3181998A
(en)
*
|
1960-08-12 |
1965-05-04 |
Joseph L Kanig |
Tablet disintegration
|
|
US3147187A
(en)
*
|
1962-09-10 |
1964-09-01 |
Don Hall Lab |
Sustained release pharmaceutical
|
|
US5019302A
(en)
*
|
1986-03-12 |
1991-05-28 |
Washington University Technology Associates, Inc. |
Method for granulation
|
|
US6632429B1
(en)
|
1999-12-17 |
2003-10-14 |
Joan M. Fallon |
Methods for treating pervasive development disorders
|
|
US20070053895A1
(en)
|
2000-08-14 |
2007-03-08 |
Fallon Joan M |
Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
|
|
US8030002B2
(en)
|
2000-11-16 |
2011-10-04 |
Curemark Llc |
Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
|
|
US20080058282A1
(en)
|
2005-08-30 |
2008-03-06 |
Fallon Joan M |
Use of lactulose in the treatment of autism
|
|
US8658163B2
(en)
|
2008-03-13 |
2014-02-25 |
Curemark Llc |
Compositions and use thereof for treating symptoms of preeclampsia
|
|
US8084025B2
(en)
|
2008-04-18 |
2011-12-27 |
Curemark Llc |
Method for the treatment of the symptoms of drug and alcohol addiction
|
|
US9320780B2
(en)
|
2008-06-26 |
2016-04-26 |
Curemark Llc |
Methods and compositions for the treatment of symptoms of Williams Syndrome
|
|
ES2732453T3
(es)
|
2008-07-01 |
2019-11-22 |
Curemark Llc |
Métodos y composiciones para el tratamiento de síntomas de trastornos neurológicos y de salud mental
|
|
US10776453B2
(en)
|
2008-08-04 |
2020-09-15 |
Galenagen, Llc |
Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
|
|
US20100092447A1
(en)
|
2008-10-03 |
2010-04-15 |
Fallon Joan M |
Methods and compositions for the treatment of symptoms of prion diseases
|
|
ES2882518T3
(es)
|
2009-01-06 |
2021-12-02 |
Galenagen Llc |
Composición que comprende proteasa, amilasa y lipasa
|
|
CA2747703C
(en)
|
2009-01-06 |
2021-06-15 |
Curemark Llc |
Compositions and methods for the treatment or the prevention of infections by e. coli
|
|
US9056050B2
(en)
|
2009-04-13 |
2015-06-16 |
Curemark Llc |
Enzyme delivery systems and methods of preparation and use
|
|
WO2011050135A1
(en)
|
2009-10-21 |
2011-04-28 |
Curemark Llc |
Methods and compositions for the prevention and treatment of influenza
|
|
WO2011159798A2
(en)
*
|
2010-06-15 |
2011-12-22 |
University Of South Florida |
A method of modulated exothermic chemical systems through phase change materials
|
|
WO2012067621A1
(en)
*
|
2010-11-19 |
2012-05-24 |
Curemark Llc |
Preparation and use of combination enzyme and gastrointestinal modulator delivery systems
|
|
GB2503852B
(en)
|
2011-04-21 |
2018-12-12 |
Curemark Llc |
Compounds for the treatment of neuropsychiatric disorders
|
|
US10350278B2
(en)
|
2012-05-30 |
2019-07-16 |
Curemark, Llc |
Methods of treating Celiac disease
|
|
AU2018250823A1
(en)
|
2017-04-10 |
2019-10-17 |
Curemark, Llc |
Compositions for treating addiction
|
|
US11541009B2
(en)
|
2020-09-10 |
2023-01-03 |
Curemark, Llc |
Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
|